December 1, 2011
By:Cheryl Guttman Krader
Findings from a recent pooled analysis including data from patients with chronic plaque psoriasis receiving ustekinumab (Stelara, Janssen Biotech) for up to four years show that rates of adverse events associated with this biologic treatment are remaining stable over time, says Kenneth B. Gordon, M.D.
 |
November 2, 2011
By:Bill Gillette
New research suggests that the experimental drug briakinumab — withdrawn from the U.S. regulatory approval process earlier this year — is more effective in treating psoriasis than methotrexate, although use of the new drug may carry higher risks.
|
September 14, 2011
By:Bill Gillette
The Food and Drug Administration (FDA) has updated the boxed warning for all tumor necrosis factor alpha (TNF-alpha) inhibitors to include the risk of infection from the bacteria legionella and listeria, MedPage Today reports.
|
August 31, 2011
By:Bill Gillette
A review of published studies suggests that a new, effective class of psoriasis drugs may not raise the risk of heart problems, but researchers say the analysis is likely too small to detect rare cases, Reuters reports.
|
August 17, 2011
By:Bill Gillette
Environmental factors, injuries and occupations that involve heavy lifting are significantly associated with the development of psoriatic arthritis (PsA), HealthDay News reports.
|
August 3, 2011
By:Bill Gillette
Recently published study results suggest that distinct antigen-specific T-cell responses may play a role in the pathogenesis of psoriasis and atopic eczema, HealthDay News reports.
|
July 27, 2011
By:Bill Gillette
Patients with psoriatic arthritis (PsA) have a high prevalence of vitamin D insufficiency, HealthDay News reports.
|
June 1, 2011
By:Bill Gillette
Results of a new study suggest that severe psoriasis doubles the likelihood of metabolic syndrome, and that the prevalence of each syndrome component — including obesity, hypertriglyceridemia and elevated glucose — increases with severity of the skin disease, MedPageToday reports.
|
April 27, 2011
By:Bill Gillette
LEO Pharma, the U.S. affiliate of Danish firm LEO Pharma A/S, is offering a copay program for many users of its Taclonex Ointment and Taclonex Scalp Topical Suspension (calcipotriene 0.005 percent, betamethasone dipropionate 0.064 percent) psoriasis medications.
|
| 
Practice Tools
